Emcure Pharmaceuticals share price makes a strong debut, stock opens with 31.5% premium at ₹1,325.05 apiece on NSE

-


Emcure Pharmaceuticals share price lists on the bourses today.


Emcure Pharmaceuticals share price made a strong debut on the bourses today. On NSE and BSE, Emcure Pharmaceuticals share price opened at ₹1,325.05 per share, 31.45% higher than the issue price of ₹1,008.

Market experts anticipated Emcure Pharmaceuticals share price to open in the range of ₹1,370 to ₹1,390 apiece.

All sections of the Emcure Pharma IPO were oversubscribed on the third day of the bidding process, with non-institutional investors leading the way. According to BSE data, Emcure Pharmaceuticals IPO subscription status was 67.87 times.

The retail investors component was booked 7.21 times, while the non-institutional investors received a subscription 48.32 times. The employee component has 8.81 times as many subscriptions as the qualified institutional buyer (QIB), with 195.83 subscriptions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         













Comments

Post a Comment

Popular posts from this blog

Cell therapy weekly: partnerships for advancing cell and gene therapies

-
Image
This week: Partnerships to advance cell and gene therapies have been announced, focusing on three key areas: developing gene therapies, enhancing cell and gene therapy manufacturing and developing treatments for difficult-to-treat conditions. The news highlights:Centers of excellence for gene therapy research Advancing cell and gene therapy manufacturing Developing therapies for difficult-to-treat conditions Centers of excellence for gene therapy research The Medical Research Centre (MRC), part of UK Research and Innovation (UKRI; both Swindon, UK) is establishing two Centers of Research Excellence (CoRE) to advance therapies for untreatable diseases, each receiving up to roughly US$64 million over 14 years aiming to transform treatments for diseases such as heart disease, immune disorders and neurodegenerative diseases like Huntington’s disease. Oxford University (UK) will lead the MRC/BHF CoRE in Advanced Cardiac Therapies, which will be co-funded with the British Heart Foundati...
Read more

DBT, CSCR develop 1st human gene therapy for Haemophilia A in India

-
Image
Offering hope to around 136,000 Haemophilia A patients in India, the Department of Biotechnology (DBT), along with the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore, announced that they have successfully executed a first-in-human gene therapy using lentiviral vectors for the disease. Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal and external bleeding episodes. Although rare, India bears the world’s second-largest burden of haemophilia. Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, intravenous (IV) access in children, and low patient acceptance.The single-centre study, which enrolled five participants aged between 22 and 41 years, showed transformational results, according to scientists involved in the research. “The therapy successfully produced zero annualised bleeding rates in all five enrolled participan...
Read more